Advanced glycation end-products produced systemically and by macrophages: a common contributor to inflammation and degenerative diseases

Kyunghee Byun, Yong Cheol Yoo, Myeongjoo Son, Jaesuk Lee, Goo-Bo Jeong, Young Mok Park, Ghasem Hosseini Salekdeh, Bonghee Lee

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Advanced glycation end products (AGEs) and their receptor have been implicated in the progressions of many intractable diseases, such as diabetes and atherosclerosis, and are also critical for pathologic changes in chronic degenerative diseases, such as Alzheimer's disease, Parkinson's disease, and alcoholic brain damage. Recently activated macrophages were found to be a source of AGEs, and the most abundant form of AGEs, AGE-albumin excreted by macrophages has been implicated in these diseases and to act through common pathways. AGEs inhibition has been shown to prevent the pathogenesis of AGEs-related diseases in human, and therapeutic advances have resulted in several agents that prevent their adverse effects. Recently, anti-inflammatory molecules that inhibit AGEs have been shown to be good candidates for ameliorating diabetic complications as well as degenerative diseases. This review was undertaken to present, discuss, and clarify current understanding regarding AGEs formation in association with macrophages, different diseases, therapeutic and diagnostic strategy and links with RAGE inhibition.

LanguageEnglish
Pages44-55
Number of pages12
JournalPharmacology and Therapeutics
Volume177
DOIs
Publication statusPublished - Sep 2017
Externally publishedYes

Fingerprint

Advanced Glycosylation End Products
Macrophages
Inflammation
Diabetes Complications
Parkinson Disease
Albumins
Atherosclerosis
Alzheimer Disease
Chronic Disease
Anti-Inflammatory Agents
Brain
Therapeutics

Bibliographical note

Copyright the Author(s) 2017. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • Advanced glycation end products (AGEs)
  • Receptor for AGEs (RAGE)
  • Macrophage
  • Inflammation
  • Degenerative diseases

Cite this

Byun, Kyunghee ; Yoo, Yong Cheol ; Son, Myeongjoo ; Lee, Jaesuk ; Jeong, Goo-Bo ; Park, Young Mok ; Salekdeh, Ghasem Hosseini ; Lee, Bonghee. / Advanced glycation end-products produced systemically and by macrophages : a common contributor to inflammation and degenerative diseases. In: Pharmacology and Therapeutics. 2017 ; Vol. 177. pp. 44-55.
@article{4110f2bd01d94731b0a405dfe23e21bb,
title = "Advanced glycation end-products produced systemically and by macrophages: a common contributor to inflammation and degenerative diseases",
abstract = "Advanced glycation end products (AGEs) and their receptor have been implicated in the progressions of many intractable diseases, such as diabetes and atherosclerosis, and are also critical for pathologic changes in chronic degenerative diseases, such as Alzheimer's disease, Parkinson's disease, and alcoholic brain damage. Recently activated macrophages were found to be a source of AGEs, and the most abundant form of AGEs, AGE-albumin excreted by macrophages has been implicated in these diseases and to act through common pathways. AGEs inhibition has been shown to prevent the pathogenesis of AGEs-related diseases in human, and therapeutic advances have resulted in several agents that prevent their adverse effects. Recently, anti-inflammatory molecules that inhibit AGEs have been shown to be good candidates for ameliorating diabetic complications as well as degenerative diseases. This review was undertaken to present, discuss, and clarify current understanding regarding AGEs formation in association with macrophages, different diseases, therapeutic and diagnostic strategy and links with RAGE inhibition.",
keywords = "Advanced glycation end products (AGEs), Receptor for AGEs (RAGE), Macrophage, Inflammation, Degenerative diseases",
author = "Kyunghee Byun and Yoo, {Yong Cheol} and Myeongjoo Son and Jaesuk Lee and Goo-Bo Jeong and Park, {Young Mok} and Salekdeh, {Ghasem Hosseini} and Bonghee Lee",
note = "Copyright the Author(s) 2017. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",
year = "2017",
month = "9",
doi = "10.1016/j.pharmthera.2017.02.030",
language = "English",
volume = "177",
pages = "44--55",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier",

}

Advanced glycation end-products produced systemically and by macrophages : a common contributor to inflammation and degenerative diseases. / Byun, Kyunghee; Yoo, Yong Cheol; Son, Myeongjoo; Lee, Jaesuk; Jeong, Goo-Bo; Park, Young Mok; Salekdeh, Ghasem Hosseini; Lee, Bonghee.

In: Pharmacology and Therapeutics, Vol. 177, 09.2017, p. 44-55.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Advanced glycation end-products produced systemically and by macrophages

T2 - Pharmacology and Therapeutics

AU - Byun,Kyunghee

AU - Yoo,Yong Cheol

AU - Son,Myeongjoo

AU - Lee,Jaesuk

AU - Jeong,Goo-Bo

AU - Park,Young Mok

AU - Salekdeh,Ghasem Hosseini

AU - Lee,Bonghee

N1 - Copyright the Author(s) 2017. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2017/9

Y1 - 2017/9

N2 - Advanced glycation end products (AGEs) and their receptor have been implicated in the progressions of many intractable diseases, such as diabetes and atherosclerosis, and are also critical for pathologic changes in chronic degenerative diseases, such as Alzheimer's disease, Parkinson's disease, and alcoholic brain damage. Recently activated macrophages were found to be a source of AGEs, and the most abundant form of AGEs, AGE-albumin excreted by macrophages has been implicated in these diseases and to act through common pathways. AGEs inhibition has been shown to prevent the pathogenesis of AGEs-related diseases in human, and therapeutic advances have resulted in several agents that prevent their adverse effects. Recently, anti-inflammatory molecules that inhibit AGEs have been shown to be good candidates for ameliorating diabetic complications as well as degenerative diseases. This review was undertaken to present, discuss, and clarify current understanding regarding AGEs formation in association with macrophages, different diseases, therapeutic and diagnostic strategy and links with RAGE inhibition.

AB - Advanced glycation end products (AGEs) and their receptor have been implicated in the progressions of many intractable diseases, such as diabetes and atherosclerosis, and are also critical for pathologic changes in chronic degenerative diseases, such as Alzheimer's disease, Parkinson's disease, and alcoholic brain damage. Recently activated macrophages were found to be a source of AGEs, and the most abundant form of AGEs, AGE-albumin excreted by macrophages has been implicated in these diseases and to act through common pathways. AGEs inhibition has been shown to prevent the pathogenesis of AGEs-related diseases in human, and therapeutic advances have resulted in several agents that prevent their adverse effects. Recently, anti-inflammatory molecules that inhibit AGEs have been shown to be good candidates for ameliorating diabetic complications as well as degenerative diseases. This review was undertaken to present, discuss, and clarify current understanding regarding AGEs formation in association with macrophages, different diseases, therapeutic and diagnostic strategy and links with RAGE inhibition.

KW - Advanced glycation end products (AGEs)

KW - Receptor for AGEs (RAGE)

KW - Macrophage

KW - Inflammation

KW - Degenerative diseases

UR - http://www.scopus.com/inward/record.url?scp=85014995461&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2017.02.030

DO - 10.1016/j.pharmthera.2017.02.030

M3 - Review article

VL - 177

SP - 44

EP - 55

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -